Tag Archives: Ligand Pharma

H.C. Wainwright Reiterates a Buy Rating on Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $254. The company’s shares closed yesterday at $120.61, close to its 52-week low of

Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), OpGen Inc (OPGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND – Research Report), OpGen Inc (OPGN – Research Report) and Galectin Therapeutics (GALT – Research Report) with bullish sentiments.

H.C. Wainwright Sticks to Their Buy Rating for Ligand Pharma (LGND)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $281. The company’s shares opened today at $175.99. Pantginis observed: “Valuation and risks to price target achievement.

The SVP, GC & Sec of Ligand Pharma is Exercising Options

Today it was reported that the SVP, GC & Sec of Ligand Pharma (NASDAQ: LGND), Charles Berkman, exercised options to buy 2,000 LGND shares at $14.47 a share, for a total transaction value of $28.94K. Following Charles Berkman’s last LGND

What Did This CEO Just Do with Personal Shares of Ligand Pharma (NASDAQ: LGND)?

Today, the CEO of Ligand Pharma (NASDAQ: LGND), John L. Higgins, sold shares of LGND for $903.9K. Following John L. Higgins’ last LGND Sell transaction on November 20, 2017, the stock climbed by 127.1%. In addition to John L. Higgins,

The EVP,Finance & Strategy and CFO of Ligand Pharma is Exercising Options

Yesterday it was reported that the EVP,Finance & Strategy and CFO of Ligand Pharma (NASDAQ: LGND), Matthew Korenberg, exercised options to sell 18,357 LGND shares at $85.79 a share, for a total transaction value of $4.71M. Following Matthew Korenberg’s last